Routh JC, Grant FD, Kokorowski PJ, Nelson CP, Fahey FH, Treves St, Lee RS.
Economic and radiation costs of initial imaging approaches after a child's first febrile urinary tract infection.
Clin Pediatr. 51(1): 23-30, January 2012.
Tsivian M, Qi P, Kimura M, Chen VH, Chen SH, Gan TJ, Polascik TJ.
The effect of noise-cancelling headphones or music on pain perception and anxiety in men undergoing transrectal prostate biopsy.
Urology 79(1): 32-36, January 2012.
Zhai L, Polascik TJ, Foo WC, Rosenzweig S, Palmeri ML, Madden J, Nightingale KR.
Acoustic radiation force impulse imaging of human prostates: Initial in vivo demonstration.
Ultrasound Med Biol. 38(1): 50-61, January 2012.
Peterson AC, Chen Y.
Patient reported incontinence after radical prostatectomy is more common than expected and not associated with the nerve sparing technique: Results from the Center for Prostate Disease Research (CPDR) database.
Neurourol Urodyn. 31((1):60-63, January 2012.
Henry GD, Donatucci CF, Conners W, Greenfield JM, Carson CC, Wilson SK, Delk J, Lentz AC, Cleves MA, Jennermann CJ, Kramer AC.
An outcomes analysis of over 200 revision surgeries for penile prosthesis implantation: A multicenter study.
J Sex Med. 9(1): 309-315, January 2012.
Williams CD, Whitley BM, Hoyo C, Grant DJ, Schwartz GG, Presti JC Jr, Iraggi JD, Newman KA, Gerber L, Taylor LA, McKeever MG, Freedland SJ.
Dietary calcium and risk for prostate cancer: A case-control study among US veterans.
Prev Chronic Dis. 9:E39, January 2012.
Loeb S, Carter HB, Catalona WJ, Moul JW, Schroder FH.
Baseline PSA testing at a young age.
European Urology 61(1): 1-7, January 2012.
Stewart SB, Baņez LL, Robertson CN, Freedland SJ, Polascik TJ, Xie D, Koontz BF, Vujaskovic Z, Lee WR, Armstrong AJ, Febbo PG, George DJ, Moul JW.
Utilization trends at a multidisciplinary prostate cancer clinic: Initial 5-year experience from the Duke Prostate Center.
J Urol 187(1): 103-108, January 2012.
Armstrong AJ, Moul JW, George DJ.
What to order from the prostate cancer treatment menu?
Oncology 26(1): 84-88, January 2012.
Moul JW, Dawson N.
Quality of life associated with treatment of castration-resistant prostate cancer: A review of the literature.
Cancer Investigation 30(1): 1-12, January 2012.
Tsivian M, Moreira DM, Sun L, Mouraviev V, Kimura M, Moul JW, Polascik TJ. Biopsy accuracy in identifying unilateral prostate cancer depends on prostate weight. Urologic Oncology: Seminars and Original Investigations 30(1): 21-25, January 2012.
Moul JW. Prostate cancer: Making the switch from LHRH antagonist to LHRH agonist. Nat Rev Urol 9(3): 125-126, January 2012.
George D, Moul JW.
Emerging treatment options for patients with castration-resistant prostate cancer.
The Prostate 72(3): 338-349, February 2012.
Tang P, Du W, Xie K, Fu J, Chen H, Yang W, Moul JW.
Characteristics of baseline PSA and PSA velocity in young men without prostate cancer: Racial differences.
Prostate 72(2): 173-180, February 2012.
Stephenson AJ, Bolla M, Briganti A, Cozzarini C, Moul JW, Roach M, van Poppel H, Zietman A.
Postoperative radiation therapy for pathologically advanced prostate cancer after radical prostatectomy.
European Urology 61(3): 443-450, March 2012.
Schroeck FR, Krupski TL, Stewart SB, Baņez LL, Gerber L, Albala DM, Moul JW. Pretreatment expectations of patients undergoing robotic assisted laparoscopic or open retropubic radical prostatectomy.
J Urol 187(3): 894-898, March 2012.
Lipkin ME, Wang AJ, Toncheva G, Ferrandino MN, Yoshizumi TT, Preminger GM.
Determination of patient radiation dose during ureteroscopic treatment of urolithiasis using a validated model.
J Urol. 187(3): 920-924, March 2012.
Lipkin ME, Preminger GM.
Risk reduction strategy for radiation exposure during percutaneous nephrolithotomy.
Curr Opin Urol 22(2): 139-143, March 2012.
Nambudiri VE, Landrum MB, Lamont EB, McNeil BJ, Bozeman SR, Freedland SJ, Keating NL.
Understanding variation in primary prostate cancer treatment within the Veterans Health Administration.
Urology 79(3): 537-545, March 2012.
DeNunzio C, Aronson W, Freedland SJ, Giovannucci E, Parsons JK.
The correlation between metabolic syndrome and prostatic diseases.
Eur Urol 61(3): 560-70, March 2012.
Zhang J, Denton BT, Balasubramanian H, Shah ND, Inman BA.
Optimization of PSA screening policies: A comparison of the patient and societal perspectives.
Med Decis Making 32(2): 337-349, March-April 2012.
Caso JR, Tsivian M, Mouraviev V, Kimura M, Polascik TJ.
Complications and postoperative events after cryosurgery for prostate cancer.
BJU Int. 109(6): 949-958, March 2012.
Baust JM, Klossner DP, Robilotto A, Vanbuskirk RG, Gage AA, Mouraviev V, Polascik TJ, Baust JG.
Vitamin D(3) cryosensitization increases prostate cancer susceptibility to cryoablation via mitochondrial-mediated apoptosis and necrosis.
BJU Int. 109(6): 949-958, March 2012.
Tsivian M, Wright T, Price M, Mouraviev V, Madden JF, Kimura M, Wong T, Polascik TJ.
111-In-capromab pendetide imaging using hybrid-y-camera-computer tomography technology is not reliable in detecting seminal vesicle invasion in patients with prostate cancer.
Urol Oncol 30(2): 150-154, March 2012.
Goldsmith ZG, Lipkin ME.
When (and how) to surgically treat asymptomatic renal stones.
Nat Rev Urol. 9(6): 315-320, March 2012.
Motzer RJ, Agarwal N, Beard C, Bhayani S, Bolger GB, Buyyounouski MK, Carducci MA, Chang SS, Choueiri TK, Gupta S, Hancock SL, Hudes GR, Jonasch E, Kuzel TM, Lau C, Levine EG, Lin DW, Margolin KA, Michaelson MD, Olencki T, Pili R, Ratliff TW, Redman BG, Robertson CN, Ryan CJ, Sheinfeld J, Wang J, Wilder RB.
J Natl Compr Canc Netw 10(4): 502-535, April 2012.
Bader MJ, Eisner B, Porpiglia F, Preminger GM, Tiselius HG.
Contemporary management of ureteral stones.
Eur Urol. 61(4): 764-772, April 2012.
Tsivian M, Kim CY, Caso JR, Rosenberg MD, Nelson RC, Polascik TJ.
Contrast enhancement on computed tomography after renal cryoablation: An evidence of treatment failure.
J Endourol. 26(4): 330-335, April 2012.
Open versus laparoscopic nephroureterectomy: Is there really a debate?
Eur Urol 61(4): 722-723, April 2012.
Tsivian M, Zilberman DE, Ferrandino MN, Madden JF, Mouraviev V, Albala DM.
Apical surgical margins status in robot-assisted laparoscopic radical prostatectomy does not depend on disease characteristics.
J Endourol 26(4): 361-365, April 2012.
Routh JC, Bogaert GA, Kaefer M, Manzoni G, Park JM, Retik AB, Rushton HG, Snodgrass WT, Wilcox DT.
Vesicoureteral reflux: Current trends in diagnosis, screening, and treatment.
European Urology 61(4): 773-782, April 2012.
Wang H-HS, Huang L, Routh JC, Nelson CP.
Shock wave lithotripsy vs ureteroscopy: Variation in surgical management of kidney stones at freestanding children's hospitals.
J Urol. 187(4): 1402-1407, April 2012.
Kokorowski PJ, Chow JS, Strauss K, Pennison M, Routh JC, Nelson CP.
Prospective measurement of patient exposure to radiation during pediatric ureteroscopy.
J Urol. 187(4): 1408-1415, April 2012.
Boorjian SA, Eastham JA, Graefen M, Guillonneau B, Karnes RJ, Moul JW, Schaeffer EM, Stief C, Zorn KC.
A critical analysis of the long term impact of radical prostatectomy on cancer control and function outcomes: A systemic review.
European Urology 61(4): 664-675, April 2012.
Kimura M, Baņez LL, Gerber L, Qi J, Tsivian M, Freedland SJ, Satoh T, Polascik TJ, Baba S, Moul JW.
Association between preoperative erectile dysfunction and prostate cancer features - An analysis from the Duke Prostate Center database.
J Sex Med. 9(4): 1174-1181, April 2012.
Wattson DA, Chen MH, Moul JW, Moran BJ, Dosoretz DE, Robertson CN, Polascik TJ, Braccioforte MH, Salenius SA, D'Amico AV.
The number of high-risk factors and the risk of prostate cancer - specific mortality after brachytherapy: Implications for treatment selection.
Int J Radiat Oncol Biol Phys. 82(5): e773-e779, April 2012.
Ankerst DP, Boeck A, Freedland SJ, Thompson IM, Cronin AM, Roobol MJ, Hugosson J, Jones S, Kattan MW, Klein EA, Hamdy F, Neal D, Donovan J, Parekh DJ, Klocker H, Horninger W, Benchikh A, Salama G, Villers A, Moreira DM, Schroder FH, Lilja H, Vickers AJ.
Evaluating the PCPT risk calculator in ten international biopsy cohorts: Results from the Prostate Biopsy Collaborative Group.
World J Urol. 30(2): 181-187, April 2012.
Roobol MJ, Schroder FH, Hugosson J, Jones JS, Kattan MW, Klein EA, Hamdy F, Neal D, Donovan J, Parekh DJ, Ankerst D, Bartsch G, Klocker H, Horninger W, Benchikh A, Salama G, Villers A, Freedland SJ, Moreira DM, Vickers AJ, Lilja H, Steyerberg EW.
Importance of prostate volume in the European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators: Results from the prostate biopsy collaborative group.
World J Urol. 30(2): 149-155, April 2012.
Abern MR, Tsivian M, Polascik TJ.
Focal therapy of prostate cancer: Evidence-based analysis for modern selection criteria.
Curr Urol Rep. 13(2): 160-169, April 2012.
Marberger M, Freedland SJ, Andriole GL, Emberton M, Pettaway C, Montorsi F, Teloken C, Rittmaster RS, Somerville MC, Castro R.
Usefulness of prostate-specific antigen (PSA) rise as a marker of prostate cancer in men treated with dutasteride: Lessons from the REDUCE study.
BJU Int. 109(8): 1162-1169, April 2012.
Thomas JA 2nd, Gerber L, Baņez LL, Moreira DM, Rittmaster RS, Andriole GL, Freedland SJ.
Prostate cancer risk in men with baseline history of coronary artery disease: Results from the REDUCE study.
Cancer Epidemiol Biomarkers Prev. 21(4): 576-581, April 2012.
Muller RL, Presti JC Jr, Aronson WJ, Terris MK, Kane CJ, Amling CL, Freedland SJ.
Does salvage radiation therapy change the biology of recurrent prostate cancer based on PSA doubling times? Results from the SEARCH database.
Urology 79(5): 1105-1110, May 2012.
Freedland SJ, Walter LC.
80 is the new 60: Implications of irrational exuberance regarding longevity on prostate cancer treatment decisions.
J Gen Intern Med. 27(5): 485-486, May 2012.
Lipkin ME, Mancini JG, Toncheva G, Wang AJ, Anderson-Evans C, Simmons WN, Ferrandino MN, Yoshizumi TT, Preminger GM.
Organ-specific radiation dose rates and effective dose rates during percutaneous nephrolithotomy.
J Endourol. 26(5): 439-443, May 2012.
Singh AA, Baņez LL.
J Urol. 187(5): 1593, May 2012.
European urology: An American perspective.
Eur Urol 61(6): 1197-1198, June 2012.
Bastian PJ, Boorjian SA, Bossi A, Briganti A, Heidenreich A, Freedland SJ, Montorsi F, Roach M 3rd, Schroder F, van Poppel H, Stief CG, Stephenson AJ, Zelefsky MJ.
High-risk prostate cancer: From definition to contemporary management.
Eur Urol. 61(6): 1096-1106, June 2012.
Tausch TJ, Peterson AC.
Early aggressive treatment of lichen sclerosus may prevent disease progression.
J Urol. 187(6): 2101-2105, June 2012.
Lentz AC, Peterson AC, Webster GD.
Outcomes following artificial sphincter implantation after prior unsuccessful male sling.
J Urol. 187(6): 2149-2153, June 2012.
Kopp RP, Stroup SP, Schroeck FR, Freedland SJ, Millard F, Terris MK, Aronson WJ, Presti, Jr, JC, Amling CL, Kane CJ.
Are repeat prostate biopsies safe? A cohort analysis from the SEARCH database.
J Urol. 187(6)2056-2060, June 2012.
Ahmed HU, Akin O, Coleman JA, Crane S, Emberton M, Goldenberg L, Hricak H, Kattan MW, Kurhanewicz J, Moore CM, Parker C, Polascik TJ, Scardino P, van As N, Villers A; on behalf of the Transatlantic Consensus Group on Active Surveillance and Focal Therapy for Prostate Cancer.
Transatlantic Consensus Group on active surveillance and focal therapy for prostate cancer.
BJU Int. 109(11): 1636-1647, June 2012.
Kimura M, Rabbani Zn, Zodda AR, Yan H, Jackson IL, Polascik TJ, Donatucci CF, Moul JW, Vujaskovic Z, Koontz BF.
Role of oxidative stress in a rat model of radiation-induced erectile dysfunction.
J Sex Med 9(6): 1535-1549, June 2012.
Tsivian M, Abern MR, Polascik TJ.
Prostate cancer treatment unblinded.
Lancet Oncol. 13(6): 567-568, June 2012.
So C, Kirby KA, Mehta K, Hoffman RM, Powell AA, Freedland SJ, Sirovich B, Yano EM, Walter LC.
Medical center characteristics associated with PSA screening in elderly veterans with limited life expectancy.
J Gen Intern Med. 27(6): 653-660, June 2012.